Watson W. Mark

Director Watson W. Mark buys 20,000 VXRT shares at $0.41 (2 transactions, $8,185 total)

Watson W. Mark, a director, executed 2 separate purchases totaling 20,000 shares at $0.41 per share on 2025-11-17, increasing his holdings by 19.2% to 124,125 shares. The current stock price of $0.36 is below the transaction price and stands 61.7% below the 52-week high of $0.94. Vaxart is unprofitable with net income of $-8,141,000.00 in the latest period, though it posted strong annual revenue growth of +288.9%; however, such growth in a pre-profit biotech context requires scrutiny. At this ticker, Mark's prior buy on 2025-07-29 showed a 90-day return of -11.4%, while his 2024-06-18 purchase returned +38.4% over 90 days—a 50% hit rate on timing—suggesting mixed predictive value from this insider's historical buys at this company.

Director Watson W. Mark bought 10,000 shares of VXRT at $0.40; stock now $0.37, down 19.5% in 30 days as company burns cash with $15.6M net loss despite 288.9% revenue growth.

Director Watson W. Mark purchased 10,000 shares at $0.40 on 2025-07-29, increasing his holdings from 94,125 to 104,125 shares, while Vaxart is unprofitable with a net loss of $15.6M against quarterly revenue of $20.9M. The stock has declined 19.5% over the past 30 days and currently trades at $0.37, down 62.6% from its 52-week high of $0.99. In his cross-ticker track record, Mark's prior buy resulted in a 90-day return of +38.4%, but this does not necessarily predict outcomes at VXRT—his only prior trade at this ticker on 2024-06-18 (also a buy) did achieve a 90-day return of +38.4%, though that represents a single historical data point. The purchase occurs in the context of significant cash burn (quarterly loss exceeding quarterly revenue), which remains the critical operational constraint investors should monitor.

Director Watson W. Mark purchased 20,000 shares of VXRT at $0.68 on 2024-06-18, raising holdings to 78,125 shares (+34.4%).

Watson W. Mark, a director at Vaxart, purchased 20,000 shares at $0.68 on 2024-06-18, increasing his holdings by 34.4% from 58,125 to 78,125 shares. The purchase occurred amid significant headwinds: the stock has declined 48.9% from its 52-week high of $1.41, fallen 16.3% over the prior 30 days, and dropped 42.9% over the prior 90 days. The company's fundamentals show a net income loss of $-24,417,000.00 in its latest full fiscal year, though quarterly revenue of $2,181,000.00 reflects 6796.3% annual revenue growth. The substantial percentage increase in the director's personal holding stake, paired with a material decline in share price and the company's unprofitable position, warrants investor scrutiny into the director's basis for the acquisition and the company's path to profitability.